Colonial Trust Co SC lowered its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 3.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 16,161 shares of the company’s stock after selling 503 shares during the quarter. Eli Lilly and Company accounts for 2.4% of Colonial Trust Co SC’s portfolio, making the stock its 5th biggest position. Colonial Trust Co SC’s holdings in Eli Lilly and Company were worth $18,700,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently made changes to their positions in LLY. Bank of America Corp DE bought a new position in shares of Eli Lilly and Company during the second quarter valued at about $13,522,666,000. Jupiter Topco LLC bought a new stake in shares of Eli Lilly and Company in the second quarter worth about $4,667,180,000. Corient Private Wealth LP bought a new stake in shares of Eli Lilly and Company in the second quarter worth about $764,116,000. BlackRock Inc. increased its holdings in Eli Lilly and Company by 1.6% during the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock valued at $81,009,981,000 after purchasing an additional 1,046,558 shares during the period. Finally, State Street Corp increased its holdings in Eli Lilly and Company by 1.7% during the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company’s stock valued at $43,438,262,000 after purchasing an additional 605,752 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.
Eli Lilly and Company Stock Down 2.4%
LLY stock opened at $1,380.92 on Thursday. Eli Lilly and Company has a fifty-two week low of $850.51 and a fifty-two week high of $1,475.25. The business’s 50 day moving average price is $1,258.86 and its two-hundred day moving average price is $1,115.99. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The company has a market capitalization of $1.30 trillion, a price-to-earnings ratio of 44.31, a price-to-earnings-growth ratio of 1.69 and a beta of 0.40.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The company had revenue of $24.40 billion during the quarter, compared to analysts’ expectations of $22.58 billion. During the same quarter last year, the business posted $7.02 EPS. The firm’s revenue for the quarter was up 38.6% compared to the same quarter last year. As a group, analysts forecast that Eli Lilly and Company will post 35.70 earnings per share for the current fiscal year.
Eli Lilly and Company Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be issued a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. Eli Lilly and Company’s dividend payout ratio is 22.46%.
Key Headlines Impacting Eli Lilly and Company
These are some of the LLY headlines that stood out recently:
- Positive Sentiment: Health Canada also cleared Mounjaro (tirzepatide) to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. The broader indication may strengthen the drug’s commercial opportunity. Article: Health Canada approves Lilly’s Mounjaro to reduce cardiovascular risk
- Neutral Sentiment: Bloomberg reported Lilly’s 2026 acquisition commitments have surpassed $32 billion. The deals could diversify growth beyond metabolic medicines, but their eventual value depends on research, clinical and regulatory outcomes. Article: Lilly Buying Spree Surpasses $32B
- Negative Sentiment: A third-party vendor linked to Lilly was reportedly hit by a data breach. Lilly said its own systems showed no unauthorized access, but an extortion group claims to possess patient and prescriber data, leaving potential privacy and reputational concerns. Article: Third-Party Vendor Linked to Eli Lilly Is Hit by Data Breach
Analysts Set New Price Targets
A number of research analysts have commented on LLY shares. Argus upped their price target on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Bank of America reiterated a “buy” rating and issued a $1,497.00 price objective on shares of Eli Lilly and Company in a research report on Friday, October 30th. Truist Financial reissued a “buy” rating and set a $1,612.00 target price (up from $1,376.00) on shares of Eli Lilly and Company in a research note on Friday, October 30th. Berenberg Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price target for the company in a research note on Tuesday, September 15th. Finally, Weiss Ratings raised Eli Lilly and Company from a “buy (b)” rating to a “buy (b+)” rating in a research note on Friday, November 13th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,422.00.
Get Our Latest Research Report on LLY
Insider Buying and Selling
In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the transaction, the executive vice president owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. This trade represents a 54.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.14% of the company’s stock.
About Eli Lilly and Company
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
Featured Articles
- Five stocks we like better than Eli Lilly and Company
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
